• Mineralys presented new post hoc Phase 3 Launch-HTN data at ESH 2026 on lorundrostat in uncontrolled or resistant hypertension with chronic kidney disease.
• The analysis showed clinically meaningful blood pressure reductions in chronic kidney disease patients, broadly comparable with outcomes in participants without kidney disease.
• In chronic kidney disease patients with baseline albuminuria, lorundrostat lowered a key marker of kidney damage versus placebo.
• Safety was described as favorable across kidney disease subgroups, with low confirmed hyperkalemia rates over 12 weeks.
• Lorundrostat is under FDA review, with a PDUFA target date of December 22, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605301115PRIMZONEFULLFEED9727644) on May 30, 2026, and is solely responsible for the information contained therein.